睿智医药(300149) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥268,658,644.91, a decrease of 30.45% compared to ¥386,301,922.70 in the same period last year[4] - The net profit attributable to shareholders for Q1 2023 was a loss of ¥28,566,911.66, representing a decline of 401.63% from a profit of ¥9,470,996.67 in Q1 2022[4] - The basic and diluted earnings per share for Q1 2023 were both -¥0.0574, a decline of 402.11% from ¥0.0190 in Q1 2022[4] - Total operating revenue for Q1 2023 was CNY 268,658,644.91, a decrease of 30.5% compared to CNY 386,301,922.70 in the same period last year[18] - Net profit for Q1 2023 was a loss of CNY 28,595,596.14, compared to a profit of CNY 9,416,742.22 in Q1 2022, marking a significant decline[19] - Earnings per share for Q1 2023 was CNY -0.0574, compared to CNY 0.0190 in the same quarter last year[20] Cash Flow - The net cash flow from operating activities was -¥20,654,400.58, a decrease of 159.11% compared to ¥34,944,776.30 in the previous year[4] - The company reported a net cash outflow from operating activities of CNY -20,654,400.58, contrasting with a net inflow of CNY 34,944,776.30 in the previous year[21] - Cash flow from investing activities showed a net inflow of ¥215,815,097.92, a significant increase of 663.05% compared to -¥38,329,695.69 in the previous year[8] - The net cash flow from investment activities was 215,815,097.92 CNY, compared to a negative cash flow of -38,329,695.69 CNY in the previous period[23] - Cash inflow from financing activities totaled 30,000,000.00 CNY, while cash outflow was 299,984,196.03 CNY, resulting in a net cash flow of -269,984,196.03 CNY[23] - The company incurred a cash outflow of 288,702,550.13 CNY for debt repayment during the financing activities[23] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥3,482,725,233.96, down 8.92% from ¥3,823,897,141.71 at the end of the previous year[4] - The total liabilities decreased to CNY 1,130,773,989.50 from CNY 1,437,935,834.66, reflecting a reduction of approximately 21.3%[16] - Total current assets decreased to ¥869,398,720.68 from ¥1,280,359,412.36, representing a decline of about 32%[15] - Total current liabilities decreased to ¥588,480,406.09 from ¥732,030,937.52, a decline of approximately 19.6%[15] - Short-term borrowings decreased to ¥95,022,611.08 from ¥115,022,611.12, a decrease of about 17.4%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,692[9] - The largest shareholder, Beihai Baben Venture Capital Co., Ltd., holds 13.69% of shares, totaling 68,441,800 shares[9] Other Financial Metrics - The company reported non-recurring gains and losses totaling ¥4,101,157.00 for the period[5] - Research and development expenses for Q1 2023 were CNY 20,950,769.76, down 26.1% from CNY 28,398,046.08 in the previous year[18] - The company recorded investment income of CNY 3,280,955.00, significantly higher than CNY 440,243.17 in Q1 2022[19] - Other comprehensive income after tax for Q1 2023 was CNY -5,414,466.45, compared to CNY -858,641.86 in the same period last year[20] Future Outlook - The company plans to continue its market expansion and product development strategies in the upcoming quarters[10] Audit Status - The first quarter report was not audited[24]